Clinical Trials
12 trialsNCT05580770 2026-05-01
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT05382936 2025-01-09
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Stemline Therapeutics, Inc.
Phase 1 Terminated
NCT04488003 2024-06-04
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT04430348 2024-03-12
PTX-35 in Patients With Advanced Solid Tumors
Heat Biologics
Phase 1 Terminated
NCT04557384 2023-02-27
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT02553499 2019-11-04
MK-1248-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT01453387 2017-05-08
MSC2015103B in Solid Tumors
EMD Serono
Phase 1 Terminated